Paul A. Algate

919 total citations
12 papers, 528 citations indexed

About

Paul A. Algate is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Paul A. Algate has authored 12 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Pathology and Forensic Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Paul A. Algate's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Paul A. Algate is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Paul A. Algate collaborates with scholars based in United States and South Africa. Paul A. Algate's co-authors include Larry R. Rohrschneider, Gary R. Fanger, Bruce A. Woda, Barbara F. Banner, Peiguo Chu, Karen Dresser, Zhong Jiang, Jiangchun Xu, Kristen Carlberg and Shalini Verma and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Molecular and Cellular Biology.

In The Last Decade

Paul A. Algate

11 papers receiving 517 citations

Peers

Paul A. Algate
Christopher Riley United States
Dan Lu China
S. Pezzulli United States
Lee Wisner United States
X. Zhang United States
Melinda S. Gordon United States
Christopher Riley United States
Paul A. Algate
Citations per year, relative to Paul A. Algate Paul A. Algate (= 1×) peers Christopher Riley

Countries citing papers authored by Paul A. Algate

Since Specialization
Citations

This map shows the geographic impact of Paul A. Algate's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul A. Algate with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul A. Algate more than expected).

Fields of papers citing papers by Paul A. Algate

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul A. Algate. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul A. Algate. The network helps show where Paul A. Algate may publish in the future.

Co-authorship network of co-authors of Paul A. Algate

This figure shows the co-authorship network connecting the top 25 collaborators of Paul A. Algate. A scholar is included among the top collaborators of Paul A. Algate based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul A. Algate. Paul A. Algate is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Algate, Paul A., Zhi Liu, Hua Liu, et al.. (2022). Abstract 2902: Development of PSB202, a bifunctional antibody pair that target CD20 and CD37, for the treatment of B-cell malignancies. Cancer Research. 82(12_Supplement). 2902–2902. 1 indexed citations
2.
Chugh, Rashmi, Judy S. Wang, Anthony J. Olszanski, et al.. (2022). Safety of dual checkpoint-blockade with PSB205, an anti-PD-1/CTLA4 monoclonal antibody combination, manufactured and dispensed as a single product: A phase 1 study.. Journal of Clinical Oncology. 40(16_suppl). 2611–2611. 1 indexed citations
3.
Hernández‐Hoyos, Gabriela, Maria Dasovich, Hang Fang, et al.. (2016). MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics. 15(9). 2155–2165. 56 indexed citations
4.
Lapalombella, Rosa, Asha Ramanunni, Yuh-Ying Yeh, et al.. (2011). Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Blood. 118(21). 622–622. 4 indexed citations
5.
Zhao, Xiaoxian, Lisa Durkin, Mien Sho, et al.. (2010). CD37 Is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma. Blood. 116(21). 3098–3098. 4 indexed citations
6.
Algate, Paul A., C. Nilsson, Mien Sho, et al.. (2010). TRU-016, An Anti-CD37 SMIP™ Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin's Lymphoma. Blood. 116(21). 3931–3931. 6 indexed citations
7.
Jiang, Zhong, Gary R. Fanger, Bruce A. Woda, et al.. (2003). Expression of α-methylacyl-coa racemase (p504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Human Pathology. 34(8). 792–796. 144 indexed citations
8.
Jiang, Zhong, Gary R. Fanger, Barbara F. Banner, et al.. (2003). A dietary enzyme: α-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detection and Prevention. 27(6). 422–426. 69 indexed citations
9.
Wolf, Ingrid, David Lucas, Paul A. Algate, & Larry R. Rohrschneider. (2000). Cloning of the Genomic Locus of Mouse SH2 Containing Inositol 5-Phosphatase (SHIP) and a Novel 110-kDa Splice Isoform, SHIPδ. Genomics. 69(1). 104–112. 23 indexed citations
10.
Sattler, Martin, Shalini Verma, Gautam Shrikhande, et al.. (1999). BCR/ABL Directly Inhibits Expression of SHIP, an SH2-Containing Polyinositol-5-Phosphatase Involved in the Regulation of Hematopoiesis. Molecular and Cellular Biology. 19(11). 7473–7480. 94 indexed citations
11.
Rohrschneider, Larry R., Roland P. Bourette, Mario N. Lioubin, et al.. (1997). Growth and differentiation signals regulated by the M-CSF receptor. Molecular Reproduction and Development. 46(1). 96–103. 58 indexed citations
12.
Algate, Paul A., Kristen Carlberg, Dave Flowers, et al.. (1997). The Human SHIP Gene Is Differentially Expressed in Cell Lineages of the Bone Marrow and Blood. Blood. 89(6). 1876–1885. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026